![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Camurus Wins FDA Fast Track Designation for Opioid Addiction Drug
Camurus Wins FDA Fast Track Designation for Opioid Addiction Drug
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
The FDA has granted fast track designation to an injectable opioid addiction drug developed by Camurus.
CAM2038 buprenorphine subcutaneous injection products are being developed as once-weekly and once-monthly formulations, each with multiple doses. Braeburn in-licensed the drug from Camurus last year for exclusive U.S. rights.
Upcoming Events
-
21Oct